These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28614387)

  • 1. Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.
    Cairns TM; Ditto NT; Lou H; Brooks BD; Atanasiu D; Eisenberg RJ; Cohen GH
    PLoS Pathog; 2017 Jun; 13(6):e1006430. PubMed ID: 28614387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
    Awasthi S; Belshe RB; Friedman HM
    J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D.
    Whitbeck JC; Huang ZY; Cairns TM; Gallagher JR; Lou H; Ponce-de-Leon M; Belshe RB; Eisenberg RJ; Cohen GH
    J Virol; 2014 Jul; 88(14):7786-95. PubMed ID: 24789783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
    Cairns TM; Huang ZY; Gallagher JR; Lin Y; Lou H; Whitbeck JC; Wald A; Cohen GH; Eisenberg RJ
    J Virol; 2015 Sep; 89(18):9213-31. PubMed ID: 26109729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
    PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S; Huang J; Shaw C; Friedman HM
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.
    Egan KP; Hook LM; Naughton A; Pardi N; Awasthi S; Cohen GH; Weissman D; Friedman HM
    PLoS Pathog; 2020 Jul; 16(7):e1008795. PubMed ID: 32716975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
    J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4
    Srivastava R; Roy S; Coulon PG; Vahed H; Prakash S; Dhanushkodi N; Kim GJ; Fouladi MA; Campo J; Teng AA; Liang X; Schaefer H; BenMohamed L
    J Virol; 2019 May; 93(9):. PubMed ID: 30787156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the antibody neutralization of herpes simplex virus.
    Lee CC; Lin LL; Chan WE; Ko TP; Lai JS; Wang AH
    Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):1935-45. PubMed ID: 24100313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic structure of soluble herpes simplex virus (HSV) glycoprotein D correlates with inhibition of HSV infection.
    Nicola AV; Peng C; Lou H; Cohen GH; Eisenberg RJ
    J Virol; 1997 Apr; 71(4):2940-6. PubMed ID: 9060653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
    Du R; Wang L; Xu H; Wang Z; Zhang T; Wang M; Ning Y; Deng F; Hu Z; Wang H; Li Y
    Antiviral Res; 2017 Nov; 147():131-141. PubMed ID: 29061442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linear Multiepitope (Glyco)peptides for Type-Specific Serology of Herpes Simplex Virus (HSV) Infections.
    Risinger C; Sørensen KK; Jensen KJ; Olofsson S; Bergström T; Blixt O
    ACS Infect Dis; 2017 May; 3(5):360-367. PubMed ID: 28238255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.
    Akhrameyeva NV; Zhang P; Sugiyama N; Behar SM; Yao F
    J Virol; 2011 May; 85(10):5036-47. PubMed ID: 21389121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
    Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.